无创血糖仪产品介绍1《IntegrityApplications》.pptx

1;This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and various provisions of the U.S. Securities Act of 1933, as amended, and the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this presentation are forward-looking statements. Forward-looking statements included in this presentation address, among other things, our future product development activities, strategies and timing of seeking regulatory approval to market?our current product candidate. These statements are based on certain historical trends, current conditions and expected future developments as well as other factors the Company believes are appropriate in the circumstances. In addition to statements which explicitly describe these risks and uncertainties, readers are urged to consider statements labeled with the terms “expects”, “anticipates” and other similar words and phrases to be uncertain and forward-looking. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the Company or its business or operations. Whether actual results will conform to the Company’s expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. See??the risks described in our reports filed with the Securities and Exchange Commission, including?under the heading Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2012.;Integrity Applications;4;;Benefits of Frequent Glucose Monitoring;HbA1c as a Function of SMBG;Importance of SMBG is Recognized!;Yet Significant Barriers Exist;Why GlucoTrack?;11;GlucoTrack? Model DF-F;Three independe